Exploring new treatments for glioma by disrupting cell cycle regulation
Synthetic lethalities to cell cycle disruption in glioma
This study is looking at how specific compounds can help improve treatment for glioma patients by targeting certain checkpoints in the cell cycle, with the goal of finding out which types of gliomas might respond better to these new treatments alongside traditional therapies like radiation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11167559 on NIH RePORTER |
What this research studies
This research investigates how certain compounds that disrupt the cell cycle can be used to improve treatment outcomes for glioma patients. By focusing on inhibitors of the G2/M checkpoint, particularly CHK1 and CHK2, the study aims to identify which gliomas may benefit from these treatments. The researchers will evaluate the effects of various small molecules on glioma cell lines to understand their potential effectiveness. This approach seeks to enhance existing therapies that rely on DNA damage, such as radiation and alkylating agents.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with gliomas who may benefit from novel therapies targeting cell cycle regulation.
Not a fit: Patients with gliomas that do not respond to cell cycle disruption therapies may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for glioma patients, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using cell cycle inhibitors in cancer treatment, indicating that this approach may lead to significant advancements in glioma therapy.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Beroukhim, Rameen — Dana-Farber Cancer Inst
- Study coordinator: Beroukhim, Rameen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.